drugset / Trial / NCT01342094

DE-111 Against Timolol Ophthalmic Solution 0.5%

NCT01342094

Phase 3 Completed 166 enrolled Santen Pharmaceutical Co., Ltd.
Parallel-groupTriple-blindTreatment

Summary

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.

Timeline

Start
2011-05
Primary completion
2012-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject DE-111 Unknown Other
Comparator Timolol Other / unclassified 0.5 % Other